LT3160476T - Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme - Google Patents

Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme

Info

Publication number
LT3160476T
LT3160476T LTEP15812231.7T LT15812231T LT3160476T LT 3160476 T LT3160476 T LT 3160476T LT 15812231 T LT15812231 T LT 15812231T LT 3160476 T LT3160476 T LT 3160476T
Authority
LT
Lithuania
Prior art keywords
nucleotides
analogs
treatment
viral infection
substituted nucleosides
Prior art date
Application number
LTEP15812231.7T
Other languages
English (en)
Inventor
Lawrence M. Blatt
Leonid Beigelman
Julian Alexander Symons
David Bernard Smith
Original Assignee
Janssen Biopharma, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biopharma, Inc. filed Critical Janssen Biopharma, Inc.
Publication of LT3160476T publication Critical patent/LT3160476T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEP15812231.7T 2014-06-24 2015-06-22 Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme LT3160476T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462016232P 2014-06-24 2014-06-24
US201462061770P 2014-10-09 2014-10-09
PCT/US2015/037001 WO2015200219A1 (en) 2014-06-24 2015-06-22 Substituted nucleosides, nucleotides and analogs thereof

Publications (1)

Publication Number Publication Date
LT3160476T true LT3160476T (lt) 2021-04-12

Family

ID=54868668

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP15812231.7T LT3160476T (lt) 2014-06-24 2015-06-22 Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme

Country Status (19)

Country Link
US (2) US9603864B2 (lt)
EP (2) EP3797782A1 (lt)
JP (3) JP6728075B2 (lt)
CN (2) CN117379452A (lt)
AU (2) AU2015280248B2 (lt)
CA (2) CA3207106A1 (lt)
DK (1) DK3160476T3 (lt)
EA (1) EA201692535A1 (lt)
ES (1) ES2841310T3 (lt)
HR (1) HRP20202014T1 (lt)
HU (1) HUE051986T2 (lt)
IL (1) IL249628A0 (lt)
LT (1) LT3160476T (lt)
MX (1) MX2016017383A (lt)
PH (1) PH12016502564A1 (lt)
SG (1) SG11201610599TA (lt)
SI (1) SI3160476T1 (lt)
TW (1) TW201613612A (lt)
WO (1) WO2015200219A1 (lt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2794627B1 (en) 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CA2860234A1 (en) 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
AU2013361200A1 (en) 2012-12-21 2015-07-23 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2013361193B2 (en) 2012-12-21 2018-05-24 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
TW201532606A (zh) 2013-04-05 2015-09-01 Alios Biopharma Inc 使用化合物之組合治療ｃ型肝炎病毒感染
JP6453322B2 (ja) 2013-06-26 2019-01-16 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
KR102314960B1 (ko) 2013-10-11 2021-10-19 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
SI3160476T1 (sl) 2014-06-24 2021-05-31 Janssen Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi, za uporabo v zdravljenju virusne okužbe
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201702430WA (en) 2014-09-26 2017-04-27 Riboscience Llc 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication
US9908914B2 (en) 2014-10-28 2018-03-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
KR20230130175A (ko) 2014-12-26 2023-09-11 에모리 유니버시티 Ｎ4-하이드록시시티딘, 이와 관련된 유도체 및 이의 항 바이러스적 용도
US9828410B2 (en) * 2015-03-06 2017-11-28 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment
US10208045B2 (en) 2015-03-11 2019-02-19 Alios Biopharma, Inc. Aza-pyridone compounds and uses thereof
CN105503787A (zh) * 2015-12-31 2016-04-20 阜阳欣奕华材料科技有限公司 一种索非布韦中间体的纯化方法
PT3433257T (pt) 2016-03-24 2023-11-29 Novartis Ag Análogos nucleosídeos de alquinil como inibidores do rinovírus humano
US11192914B2 (en) * 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
EP4088725A1 (en) 2016-09-07 2022-11-16 ATEA Pharmaceuticals, Inc. 2'-substituted-n6-substituted purine nucleotides for the treatment of a virus from the picornaviridae family
CN110234656B (zh) 2016-09-09 2023-02-28 卡利泰拉生物科技公司 外核苷酸酶抑制剂及其使用方法
JP7016170B2 (ja) * 2016-12-16 2022-02-04 国立大学法人東海国立大学機構 ヌクレオシド誘導体及びその利用
JP7066728B2 (ja) 2017-02-01 2022-05-13 アテア ファーマシューティカルズ， インコーポレイテッド Ｃ型肝炎ウイルスの治療のためのヌクレオチドヘミ硫酸塩
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
JP2020529994A (ja) 2017-07-31 2020-10-15 ジャニュアリー セラピューティクス，インク． 有機リン酸誘導体
SG11202002295QA (en) * 2017-09-18 2020-04-29 Janssen Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
JP7173467B2 (ja) 2017-10-31 2022-11-16 ヤマサ醤油株式会社 ヌクレオシド誘導体及びその利用
AU2018378832B9 (en) 2017-12-07 2021-05-27 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
JP2021516227A (ja) * 2018-03-02 2021-07-01 ジャニュアリー セラピューティクス，インク． ナノ粒子組成物
GB2611644B (en) * 2018-03-07 2023-07-26 Univ Emory 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2021521118A (ja) 2018-04-10 2021-08-26 アテア ファーマシューティカルズ， インコーポレイテッド 肝硬変を伴うｈｃｖ感染患者の治療
KR20210142712A (ko) * 2019-04-05 2021-11-25 가부시기가이샤 닛뽕쇼꾸바이 가교형 인공 뉴클레오시드의 제조
AU2020418425A1 (en) * 2019-10-08 2022-04-14 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
US11660307B2 (en) 2020-01-27 2023-05-30 Gilead Sciences, Inc. Methods for treating SARS CoV-2 infections
TWI777411B (zh) * 2020-02-18 2022-09-11 美商基利科學股份有限公司 抗病毒化合物
TWI794742B (zh) 2020-02-18 2023-03-01 美商基利科學股份有限公司 抗病毒化合物
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
CN113387954B (zh) * 2020-03-11 2024-03-19 上海特化医药科技有限公司 一种瑞德西韦中间体的制备方法
AU2021237718B2 (en) 2020-03-20 2023-09-21 Gilead Sciences, Inc. Prodrugs of 4'-C-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
WO2021191236A1 (en) * 2020-03-27 2021-09-30 R.G.C.C. Holdings AG Nucleotide analogues for the treatment of coronaviruses
KR20220160010A (ko) * 2020-03-27 2022-12-05 스미또모 가가꾸 가부시끼가이샤 핵산 올리고머의 제조 방법
WO2021207049A1 (en) 2020-04-06 2021-10-14 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
MX2022012904A (es) * 2020-04-14 2023-01-24 Janssen Pharmaceuticals Inc Analogos del nucleosido biciclico y monociclico para el tratamiento de la hepatitis e.
EP4157272A1 (en) 2020-05-29 2023-04-05 Gilead Sciences, Inc. Remdesivir treatment methods
MX2022016405A (es) 2020-06-24 2023-01-30 Gilead Sciences Inc Análogos de nucleósido de 1¿-ciano y usos de estos.
EP4200301A1 (en) 2020-08-24 2023-06-28 Gilead Sciences, Inc. Phospholipid compounds and uses thereof
JP2023540225A (ja) 2020-08-27 2023-09-22 ギリアード サイエンシーズ， インコーポレイテッド ウイルス感染症の治療のための化合物及び方法
TWI811812B (zh) 2020-10-16 2023-08-11 美商基利科學股份有限公司 磷脂化合物及其用途
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
CN113214320A (zh) * 2021-01-23 2021-08-06 河南泰丰生物科技有限公司 一种瑞德西韦化合物的制备方法
WO2022174194A1 (en) * 2021-02-15 2022-08-18 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2024512771A (ja) 2021-04-16 2024-03-19 ギリアード サイエンシーズ， インコーポレイテッド アミドを使用してカルバヌクレオシドを調製する方法
IL309732A (en) 2021-07-09 2024-02-01 Aligos Therapeutics Inc Antiviral compounds
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
CN115721661A (zh) * 2021-09-01 2023-03-03 常晓宇 嘌呤核苷类药物预防或治疗冠状病毒感染性疾病的用途
CN113461760B (zh) * 2021-09-06 2021-12-10 南京颐媛生物医学研究院有限公司 4-硫代脱氧胸苷衍生物及其抗乙肝病毒制药应用
WO2023069495A1 (en) * 2021-10-19 2023-04-27 Alnylam Pharmaceuticals, Inc. Oligonucleotides with 2'-deoxy-2'-f-2'-c-methyl nucleotides
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN116554249A (zh) * 2022-01-28 2023-08-08 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法
WO2024034644A1 (ja) * 2022-08-10 2024-02-15 国立大学法人九州大学 核酸前駆体

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
PT1411954E (pt) * 2000-10-18 2011-03-16 Pharmasset Inc Nucleosídeos modificados para o tratamento de infecções virais e proliferação celular anormal
EP1539188B1 (en) 2001-01-22 2015-01-07 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
AU2003247084B9 (en) * 2002-06-28 2018-07-26 Centre National De La Recherche Scientifique Modified 2' and 3'-nucleoside prodrugs for treating flaviridae infections
US20040259934A1 (en) * 2003-05-01 2004-12-23 Olsen David B. Inhibiting Coronaviridae viral replication and treating Coronaviridae viral infection with nucleoside compounds
EP1656093A2 (en) * 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
WO2005020885A2 (en) * 2003-05-21 2005-03-10 Isis Pharmaceuticals, Inc. Compositions and methods for the treatment of severe acute respiratory syndrome (sars)
JP2008508319A (ja) 2004-07-29 2008-03-21 メタバシス・セラピューティクス・インコーポレイテッド 新規ヌクレオシド誘導体
US20080261913A1 (en) 2006-12-28 2008-10-23 Idenix Pharmaceuticals, Inc. Compounds and pharmaceutical compositions for the treatment of liver disorders
CN101679472B (zh) * 2007-02-28 2014-07-02 艾伯塔大学校董 用于预防或治疗病毒感染的化合物及其应用方法
WO2010015643A1 (en) 2008-08-06 2010-02-11 Novartis Ag New antiviral modified nucleosides
JP2012521359A (ja) * 2009-03-20 2012-09-13 アリオス バイオファーマ インク． 置換されたヌクレオシドアナログおよびヌクレオチドアナログ
US20100240604A1 (en) 2009-03-20 2010-09-23 Alios Biopharma, Inc. Protected nucleotide analogs
US8877731B2 (en) 2010-09-22 2014-11-04 Alios Biopharma, Inc. Azido nucleosides and nucleotide analogs
US20120070411A1 (en) 2010-09-22 2012-03-22 Alios Biopharma, Inc. Substituted nucleotide analogs
WO2012040127A1 (en) 2010-09-22 2012-03-29 Alios Biopharma, Inc. Substituted nucleotide analogs
CN102558261A (zh) * 2010-12-17 2012-07-11 中国科学院大连化学物理研究所 一种核苷酸类似物及其合成和应用
EP2655392B1 (en) 2010-12-22 2018-04-18 Alios Biopharma, Inc. Cyclic nucleotide analogs
US20140212382A1 (en) 2011-05-19 2014-07-31 Emory University Purine monophosphate prodrugs for treatment of viral infections
JP5982007B2 (ja) 2011-12-20 2016-08-31 リボサイエンス・エルエルシー Ｈｃｖｒｎａ複製の阻害薬としての２’，４’−ジフルオロ−２’−メチル置換されたヌクレオシド誘導体
CA2860234A1 (en) * 2011-12-22 2013-06-27 Alios Biopharma, Inc. Substituted phosphorothioate nucleotide analogs
EP2794627B1 (en) 2011-12-22 2018-09-26 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ631601A (en) 2012-03-21 2016-06-24 Alios Biopharma Inc Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142159A1 (en) 2012-03-21 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog
US8846896B2 (en) 2012-03-21 2014-09-30 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
EP2827875B1 (en) 2012-03-21 2018-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
NZ630805A (en) 2012-03-22 2016-01-29 Alios Biopharma Inc Pharmaceutical combinations comprising a thionucleotide analog
WO2014099941A1 (en) 2012-12-19 2014-06-26 Idenix Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
FR3000193B1 (fr) 2012-12-20 2015-01-16 Msc & Sgcc Procede et dispositif de mesure de la verticalite sur un recipient
AU2013361193B2 (en) 2012-12-21 2018-05-24 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2013361200A1 (en) 2012-12-21 2015-07-23 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2014134251A1 (en) 2013-02-28 2014-09-04 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions
WO2014164533A1 (en) 2013-03-11 2014-10-09 Vertex Pharmaceuticals Incorporated Methods of stereoselective synthesis of substituted nucleoside analogs
TW201532606A (zh) 2013-04-05 2015-09-01 Alios Biopharma Inc 使用化合物之組合治療ｃ型肝炎病毒感染
BR112015025766A2 (pt) * 2013-04-12 2017-10-17 Achillion Pharmaceuticals Inc derivado de nucleosídeo altamente ativo para o tratamento de hcv
JP6453322B2 (ja) 2013-06-26 2019-01-16 アリオス バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびそれらの類似体
CA2913206C (en) 2013-06-26 2022-08-02 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015038596A1 (en) 2013-09-11 2015-03-19 Emory University Nucleotide and nucleoside compositions and uses related thereto
KR102314960B1 (ko) 2013-10-11 2021-10-19 얀센 바이오파마, 인코퍼레이트. 치환된 뉴클레오사이드, 뉴클레오타이드 및 이의 유사체
SI3160476T1 (sl) 2014-06-24 2021-05-31 Janssen Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi, za uporabo v zdravljenju virusne okužbe
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
AU2015280245A1 (en) 2014-06-24 2017-01-05 Alios Biopharma, Inc. Methods of preparing substituted nucleotide analogs
WO2016014398A1 (en) 2014-07-22 2016-01-28 Alios Biopharma, Inc. Methods for treating paramyxoviruses
MA40404A (fr) 2014-08-05 2017-06-14 Alios Biopharma Inc Polythérapie pour traiter un paramyxovirus
US9908914B2 (en) 2014-10-28 2018-03-06 Alios Biopharma, Inc. Methods of preparing substituted nucleoside analogs
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
EP3497111A2 (en) 2016-08-12 2019-06-19 Janssen BioPharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2018081449A1 (en) 2016-10-27 2018-05-03 Alios Biopharma, Inc. Methods for treating respiratory syncytial virus infection

Also Published As

Publication number Publication date
JP7449978B2 (ja) 2024-03-14
AU2015280248B2 (en) 2021-04-08
JP7080928B2 (ja) 2022-06-06
CN106573011A (zh) 2017-04-19
JP2017519784A (ja) 2017-07-20
TW201613612A (en) 2016-04-16
HRP20202014T1 (hr) 2021-04-02
EP3160476A1 (en) 2017-05-03
EP3160476A4 (en) 2018-01-10
CN106573011A8 (zh) 2017-07-11
US20150366888A1 (en) 2015-12-24
US9603864B2 (en) 2017-03-28
PH12016502564A1 (en) 2017-04-17
SG11201610599TA (en) 2017-01-27
US10307439B2 (en) 2019-06-04
IL249628A0 (en) 2017-02-28
JP2020172511A (ja) 2020-10-22
WO2015200219A1 (en) 2015-12-30
JP6728075B2 (ja) 2020-07-22
CN117379452A (zh) 2024-01-12
SI3160476T1 (sl) 2021-05-31
AU2021204791A1 (en) 2021-08-05
DK3160476T3 (da) 2020-12-21
CA2952966A1 (en) 2015-12-30
HUE051986T2 (hu) 2021-04-28
MX2016017383A (es) 2017-08-02
AU2015280248A1 (en) 2017-01-12
ES2841310T3 (es) 2021-07-08
CA3207106A1 (en) 2015-12-30
EP3160476B1 (en) 2020-09-30
JP2022116170A (ja) 2022-08-09
US20170143749A1 (en) 2017-05-25
EP3797782A1 (en) 2021-03-31
EA201692535A1 (ru) 2017-05-31
AU2021204791B2 (en) 2023-12-07

Similar Documents

Publication Publication Date Title
LT3160476T (lt) Pakeistieji nukleozidai, nukleotidai ir jų analogai, skirti naudoti virusinių infekcijų gydyme
HK1245800A1 (zh) 被取代的核苷、核苷酸及其類似物
HK1245279A1 (zh) 取代的核苷、核苷酸及其類似物
IL273341A (en) Converted nucleosides, nucleotides and their analogs
IL249627A0 (en) Nucleosides, modified nucleotides and their analogs
IL280459A (en) Phosphoramidates for the treatment of hepatitis B virus
IL295418A (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
ZA201901061B (en) 2'-substituted-n6-substituted purine nucleotides for rna virus treatment
EP3212658A4 (en) 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
EP3288957A4 (en) NUCLEOSIDE ANALOGUE FOR THE TREATMENT OF VIRUSES OF THE FLAVIVIIDAE FAMILY AND CANCER
IL273932A (en) Methods of treatment and prevention of viral infection
HUE055592T2 (hu) Kinolinszármazékok vírusfertõzés kezelésében vagy megelõzésében történõ alkalmazásra
EP3134423A4 (en) 2' -disubstituted nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
HK1252343A1 (zh) 用於治療病毒感染的組合物和方法